Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1955784
                    [Title] => Failure to prevent most heart failure could be avoided
                    [Summary] => Until the randomized EMPA-REG-OUTCOME trial of the sodium-glucose transporter 2 (SGLT-2) inhibitors empagliflozin (Jardiance), no glucose-lowering drug available for treatment of type 2 diabetes had shown any benefit in terms of reducing diabetic patients’ elevated risk of heart failure.
                    [DatePublished] => 2019-09-29 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 1
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

sodium-glucose transporter 2

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1955784
                    [Title] => Failure to prevent most heart failure could be avoided
                    [Summary] => Until the randomized EMPA-REG-OUTCOME trial of the sodium-glucose transporter 2 (SGLT-2) inhibitors empagliflozin (Jardiance), no glucose-lowering drug available for treatment of type 2 diabetes had shown any benefit in terms of reducing diabetic patients’ elevated risk of heart failure.
                    [DatePublished] => 2019-09-29 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 1
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

abtest

Failure to prevent most heart failure could be avoided

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | September 29, 2019 - 12:00am

Until the randomized EMPA-REG-OUTCOME trial of the sodium-glucose transporter 2 (SGLT-2) inhibitors empagliflozin (Jardiance), no glucose-lowering drug available for treatment of type 2 diabetes had shown any benefit...

Opinion